Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma
We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditi...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
23 March 2015
|
| In: |
Bone marrow transplantation
Year: 2015, Jahrgang: 50, Heft: 6, Pages: 802-807 |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/bmt.2015.45 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/bmt.2015.45 Verlag, Volltext: http://www.nature.com/bmt/journal/v50/n6/full/bmt201545a.html 
|
| Verfasserangaben: | F Sahebi, S Iacobelli, AV Biezen, L Volin, P Dreger, M Michallet, PT Ljungman, T de Witte, A Henseler, NPM Schaap, L López-Corral, X Poire, J Passweg, R-M Hamljadi, SH Thomas, S Schonland, G Gahrton, C Morris, N Kröger and L Garderet on behalf of the Plasma Cell Disorders Subcommittee of the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancies Working Party |
| Zusammenfassung: | We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma. |
|---|---|
| Beschreibung: | Gesehen am 04.04.2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1476-5365 |
| DOI: | 10.1038/bmt.2015.45 |